SCHEMBL660041

SCHEMBL660041

Clc1nc2cccc(Br)c2s1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB8 P28062 2/20 0.40
PDPK1 O15530 1/20 0.39
TDP1 Q9NUW8 1/20 0.38
BACE1 P56817 1/20 0.36
ELANE P08246 1/20 0.36
ALDH1A1 P00352 3/20 0.35
AKR1B1 P15121 1/20 0.34
PLK4 O00444 1/20 0.32
AURKA O14965 1/20 0.32
DAPK3 O43293 1/20 0.32
CDK1 P06493 1/20 0.32
PIM1 P11309 1/20 0.32
CDK2 P24941 1/20 0.32
SYK P43405 1/20 0.32
CLK2 P49760 1/20 0.32
GSK3A P49840 1/20 0.32
GSK3B P49841 1/20 0.32
CSNK2A1 P68400 1/20 0.32
PRKAA1 Q13131 1/20 0.32
CAMK2B Q13554 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1851438 0.79 PSMB8 (0.59) PSMB8TDP1ALDH1A1AKR1B1HSP90AA1
SCHEMBL9305900 0.78 APP (0.46) PSMB8PDPK1TDP1ALDH1A1CDK2
SCHEMBL1619718 0.76 ASH1L (0.44) PDPK1BACE1ALDH1A1HSP90AA1HSP90AB1
SCHEMBL2749649 0.76 BACE1 (0.36) PSMB8PDPK1BACE1AKR1B1HSP90AA1
SCHEMBL663501 0.76 BACE1 (0.36) PSMB8PDPK1BACE1AKR1B1HSP90AA1
SCHEMBL25156042 0.76 RAB9A (0.42) PSMB8TDP1BACE1ALDH1A1AKR1B1
SCHEMBL2748445 0.76 PSMB8 (0.40) PSMB8TDP1ELANEALDH1A1KMT2A
SCHEMBL20969721 0.76 KDM4E (0.42) PSMB8TDP1ALDH1A1AURKADAPK3
SCHEMBL4242805 0.76 PSMB8 (0.43) PSMB8TDP1ELANEALDH1A1AKR1B1
SCHEMBL2749006 0.73 ALDH1A1 (0.58) TDP1ELANEALDH1A1KDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085073-A1 PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS INC (US) 2026-03-26 US disclosed
WO-2024059524-A1 PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. (US) 2024-03-21 WO disclosed
US-20230374007-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2023-11-23 US disclosed
US-20230374007-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2023-11-23 US disclosed
US-20230374007-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2023-11-23 US disclosed
EP-4221756-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER Astrazeneca AB (SE) 2023-08-09 EP disclosed
CN-116249554-A Compounds and their use in the treatment of cancer 阿斯利康(瑞典)有限公司 2023-06-09 CN disclosed
WO-2022069520-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2022-04-07 WO disclosed
CN-111349090-B Fused heterocyclic aromatic hydrocarbon derivative, preparation and application thereof HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2021-08-31 CN disclosed
CN-111349090-A Fused heterocyclic aromatic hydrocarbon derivative, preparation and application thereof 华中科技大学 2020-06-30 CN disclosed
US-10221168-B1 Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof Wu, Xiao Hua (US) 2019-03-05 US disclosed
US-10221168-B1 Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof Wu, Xiao Hua (US) 2019-03-05 US disclosed
US-8420052-B2 Imaging agents useful for identifying AD pathology SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2013-04-16 US disclosed
US-8378104-B2 7-aminofuropyridine derivatives OSI Pharmaceuticals, LLC (US) 2013-02-19 US disclosed
EP-2534156-A1 7-AMINOFUROPYRIDINE DERIVATIVES OSI Pharmaceuticals, LLC (US) 2012-12-19 EP disclosed
US-20120046267-A1 7-AMINOFUROPYRIDINE DERIVATIVES OSI PHARMACEUTICALS, INC. 2012-02-23 US disclosed
WO-2011100502-A1 7-AMINOFUROPYRIDINE DERIVATIVES OSI Pharmaceuticals, LLC (US) 2011-08-18 WO disclosed
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology SIEMENS MEDICAL SOLUTIONS USA, INC. 2010-04-22 US disclosed
WO-2010011964-A2 IMAGING AGENTS USEFUL FOR IDENTIFYING AD PATHOLOGY SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2010-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology APP, APBA1, PYGB PSMB8 4378/4885PDPK1 3706/4885TDP1 129/4885
US-20120046267-A1 7-AMINOFUROPYRIDINE DERIVATIVES MAP3K5, STK17A, MAPKAPK5 PSMB8 2973/4885PDPK1 510/4885TDP1 1024/4885
US-10221168-B1 Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof MAN2A1, MAN1B1, ALG1 PSMB8 2737/4885PDPK1 2352/4885TDP1 499/4885
US-20230374007-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER RARA, RARG, RARB PSMB8 3745/4885PDPK1 3804/4885TDP1 2660/4885
US-20260085073-A1 PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY MALT1, BCL6, BCL3 PSMB8 1390/4885PDPK1 1633/4885TDP1 2187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.